If you’re at #JPMWeek, check out Wednesday’s live recording of The Genetics Podcast for a conversation on translating emerging RNA and gene-editing modalities into meaningful patient benefit, featuring Alltrna CEO @mcw44.bsky.social.

bit.ly/3YxH8w5

#tRNA #StopCodonDisease #RNAsky #JPM26

At the 2nd MENA Congress for Metabolism in Health and Disease 2025, Alltrna highlighted how engineered #tRNA medicines can restore protein synthesis in liver #StopCodonDisease and inborn errors of metabolism.

metabolism.ae

#RNAsky

95% of genetic #rarediseases lack therapies. On #InternationalPodcastDay, Alltrna CEO @mcw44.bsky.social shares how engineered #tRNA medicines can restore protein production and uniquely treat many diseases with the same underlying mutation.

bit.ly/3VR6LXd

#RNAsky #StopCodonDisease

Congrats to our colleagues at Flagship Pioneering on 25 years of turning bold ideas into medicines. At Alltrna, we’re building on this legacy of #BiggerLeaps by pioneering #tRNA medicines to unify treatment across #StopCodonDisease and redefine what’s possible for patients.

#FlagshipFounded

New tRNA tech aims to rewrite rare disease treatment Explore the role of tRNA in genetic medicine and how Alltrna is revolutionizing therapies for rare genetic diseases.

Drug Target Review spotlights Alltrna’s mutation-driven strategy to expand the reach of genetic medicine. By focusing on the shared genetic cause, rather than one disease at a time, our tRNA therapeutic approach can accelerate rare disease drug development.

bit.ly/4858rUi

#StopCodonDisease

An image with Nerissa and details of Alltrna's presentation at ICIEM 2025

We’re pleased to share that Alltrna will present at the International Congress of Inborn Errors of Metabolism (ICIEM 2025), taking place September 2-6 in Kyoto, Japan.

For more info: site2.convention.co.jp/iciem2025/we...

#ICIEM2025 #RNAsky #StopCodonDisease #rarediseases #tRNA

Ancient Molecule, Modern Medicine: The Science, Strategy, & Stakeholders Behind tRNA Therapeutics <p>As we all know well, &ldquo;unearthing&rdquo; our molecules&rsquo; potential poses numerous technical and business-related challenges for young biotech companies. Here, Werner and I continue our conversation, unpacking some of these internal and external challenges the company is navigating as it strives to bring tRNA to the commercial market.</p>

Raiders of the Lost Codon Part 2: The Hunt Continues.

In this new Advancing RNA article, Alltrna CEO @mcw44.bsky.social 4.bsky.social shares how we’re navigating the scientific and strategic challenges of bringing our first #tRNA medicines to patients.

bit.ly/451yuc7

#StopCodonDisease #RNAsky

At the Propionic Acidemia Conference, we presented about how premature stop codons cause #rarediseases, like PA, and the need for #genetictesting, even after a diagnosis.

If you missed it, you can learn more about #tRNA therapeutics and #StopCodonDisease here: www.alltrna.com/stop-codon-d....

Joyner Eke’s job is about more than engineering a molecule – it’s about building a future where more families have more time. Her work in process development and purification is critical to scaling Alltrna’s #tRNA medicines.

Watch her video here: www.alltrna.com/life-at-allt...

#StopCodonDisease

Alltrna scientists presented at #RNA25 and the 2025 IRSF #RettSyndrome Scientific Meeting on our advancement of #tRNA as a new therapeutic modality to treat diseases caused by the same underlying mutation.

Thanks to our team for their outstanding work!

#StopCodonDisease #RNAsky

On Behind the Breakthroughs #podcast, Alltrna CEO @mcw44.bsky.social shares how personal experience drives our mission – and how engineered tRNAs could unlock new treatments for diseases caused by premature stop codons.

Read the Q&A & listen here: bit.ly/4mZWjZN

#tRNA #StopCodonDisease #RNAsky

Bright breakthroughs: Real stories of beating rare disease

When @mcw44.bsky.social's son was diagnosed with #Duchenne, patient groups became a lifeline. In this @science.org webinar, she shares how that shaped her leadership at Alltrna, listening to families as we develop #tRNA medicines to treat #StopCodonDisease.

www.science.org/content/webi...

#RNAsky

Alltrna will be at @cureduchenne.bsky.social's #FUTURES2025 to present on how engineered tRNA medicines may uniquely overcome nonsense mutations—also called premature termination codons—in #Duchenne, with the goal of restoring full-length dystrophin.

#StopCodonDisease #RNAsky

Proud to share that @mcw44.bsky.social is delivering the 𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗿𝘁 𝗟𝗲𝗰𝘁𝘂𝗿𝗲 at #ASCPT2025! Her talk will spotlight how empathy and innovation can transform #raredisease #drugdevelopment.

@ascptclinpharm.bsky.social: bit.ly/3F4XyWt

#tRNA #StopCodonDisease #RNAsky #PatientCentricity

"Raiders Of The Lost Codon:" Alltrna On Evolving "Ancient" tRNA Into Therapeutics <p>Here, in part one of this two-part article, we identify how tRNA stands apart from other RNA modalities and gene therapies, as well as how this molecule&rsquo;s unique &ldquo;skill set&rdquo; is gu...

𝙍𝙖𝙞𝙙𝙚𝙧𝙨 𝙤𝙛 𝙩𝙝𝙚 𝙇𝙤𝙨𝙩 𝘾𝙤𝙙𝙤𝙣? #tRNA may be ancient, but its therapeutic future is just beginning. In this new article, Alltrna CEO @mcw44.bsky.social shares how we’re using tRNA’s universal biology to potentially treat many diseases.

bit.ly/3RNGuar

#StopCodonDisease #RNAsky

Alltrna’s presentation at #TIDESUSA will highlight preclinical data supporting the potential of #tRNA therapeutics to restore full-length protein synthesis in diseases caused by premature termination codons.

#StopCodonDisease #BIOsky #RNAsky

tRNA is emerging as a powerful new therapeutic approach for #rarediseases. Drug Discovery News highlights how Alltrna is advancing #tRNA medicines to restore protein function across many diseases.

Read the article here: bit.ly/3QYlH3o

#StopCodonDisease

Proud to see Alltrna scientists sharing their work at two Gordon Research Conferences! We’re honored to contribute to the scientific dialogue driving forward innovation in #tRNA therapeutics.

#StopCodonDisease

At Alltrna, we believe tRNA is key to unlocking new possibilities in medicine. In this BioSpace feature, our CEO @mcw44.bsky.social shares what drives her–and why our work could build a new future for patients.

bit.ly/3E7SOyX

#tRNA #StopCodonDisease #rarediseases

tRNA therapeutics may help restore full-length proteins in muscle #StopCodonDisease. At @mda.org's Annual Conference, Stephen Eichhorn will discuss developing engineered #tRNA therapeutics to address premature termination codons in #rarediseases, like #musculardystrophy.

www.mdaconference.org

Sandra Visser, SVP, Head of Therapeutics Development at Alltrna, will speak at the SAPA-GP Annual Conference on the development of #tRNA therapeutics for #StopCodonDisease and applying quantitative medicine to advance tRNA as a new therapeutic modality.

sapagp.org/event/sapa-g...

Looking forward to 𝗢𝗣𝗧 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟱, where Alltrna CTO William Kiesman will present on designing, manufacturing, and delivering #tRNA therapeutics for #StopCodonDisease. He will also join a breakout discussion on optimizing new RNA modalities as therapeutics.

bit.ly/41RGnAe

#RNAsky

In this interview for 𝗧𝗵𝗲 𝗚𝗲𝗻𝗲𝘁𝗶𝗰𝘀 𝗣𝗼𝗱𝗰𝗮𝘀𝘁, Alltrna CEO @mcw44.bsky.social talks about the sense of urgency that drives her work. She also shares encouraging preclinical data in #StopCodonDisease mouse models of two #rarediseases – MMA and PKU.

Full interview here: www.youtube.com/watch?v=gzSI...